With these anti-VEGF medications for ROP, there is a need for caution regarding reactivation, and the presence of peripheral retinal avascular zones, known as persistent avascular retina (PAR), is frequently observed post-treatment. The gene discussed is VEGFA; the disease is retinopathy of prematurity.